CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome

Clinical Immunology

Volumn 143, Issue 2, 2012, Pages 152-161

  Fan, Xiying ^a   Upadhyaya, Bhaskar ^a   Wu, Liming ^a   Koh, Christopher ^b   Santín Durán, Mónica ^g   Pittaluga, Stefania ^d   Uzel, Gulbu ^a   Kleiner, David ^d   Williams, Ester ^c   Ma, Chi A ^a   Bodansky, Aaron ^a   Oliveira, Joao B ^c   Edmonds, Pamela ^a   Hornung, Ronald ^f   Wong, Duane W ^e   Fayer, Ronald ^g   Fleisher, Tom ^c   Heller, Theo ^b   Prussin, Calman ^a   Jain, Ashish ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Arizona Allergy Associates   (United States)

^f SAIC FREDERICK INC   (United States)

^g U S DEPARTMENT OF AGRICULTURE   (United States)

Author keywords

CD40 ligand; CD40 R internalization; CP 870,893; X linked hyper IgM syndrome

Indexed keywords

AZITHROMYCIN; CP 870893; GAMMA INTERFERON; NITAZOXANIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ADOLESCENT; ADULT; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CASE REPORT; CLINICAL TRIAL; CRYPTOSPORIDIOSIS; CYTOKINE RELEASE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HYPER IGM SYNDROME; IN VIVO STUDY; LEUKOCYTE; MALE; MONOCYTE; OOCYST; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; X LINKED HYPER IGM SYNDROME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CD40 LIGAND; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; CYTOKINES; FECES; HUMANS; HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; MALE; T-LYMPHOCYTES;

EID: 84859759018     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.01.014     Document Type: Article

References (37)

1. Notarangelo L.D., Duse M., Ugazio A.G. Immunodeficiency with hyper-IgM (HIM). Immunodefic. Rev. 1992, 3:101-121.
2. Korthauer U., et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993, 361:539-541.
3. Aruffo A., et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993, 72:291-300.
4. Elgueta R., et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 2009, 229:152-172.
5. DiSanto J.P., Bonnefoy J.Y., Gauchat J.F., Fischer A., de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993, 361:541-543.
6. Bhushan A., Covey L.R. CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes. Immunol. Res. 2001, 24:311-324.
7. Winkelstein J.A., et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003, 82:373-384.
8. Lougaris V., Badolato R., Ferrari S., Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol. Rev. 2005, 203:48-66.
9. Castigli E., et al. CD40 ligand/CD40 deficiency. Int. Arch. Allergy Immunol. 1995, 107:37-39.
10. Caux C., et al. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 1994, 180:1263-1272.
11. Cella M., et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 1996, 184:747-752.
12. Aghamohammadi A., et al. Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations. J. Clin. Immunol. 2009, 29:769-776.
13. Levy J., et al. Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr. 1997, 131:47-54.
14. Hayward A.R., et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 1997, 158:977-983.
15. Grewal I.S., Xu J., Flavell R.A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995, 378:617-620.
16. Bayrakci B., et al. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk. J. Pediatr. 2005, 47:239-246.
17. Schneider L.C. X-linked hyper IgM syndrome. Clin. Rev. Allergy Immunol. 2000, 19:205-215.
18. Pantenburg B., et al. Human CD8(+) T cells clear Cryptosporidium parvum from infected intestinal epithelial cells. Am. J. Trop. Med. Hyg. 2010, 82:600-607.
19. Yang Y., Wilson J.M. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996, 273:1862-1864.
20. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
21. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
22. Beatty G.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
23. Gladue R.P., et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol. Immunother. 2011, 60:1009-1017.
24. Carpenter E.L., Mick R., Ruter J., Vonderheide R.H. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J. Transl. Med. 2009, 7:93.
25. Ruter J., Antonia S.J., Burris H.A., Huhn R.D., Vonderheide R.H. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol. Ther. 2010, 10:983-993.
26. Fuss I.J., Kanof M.E., Smith P.D., Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr. Protoc. Immunol. 2009, 85:7.1.1-7.1.8.
27. Rich R.R., Mollick J.A., Cook R.G. Superantigens: interaction of staphylococcal enterotoxins with MHC class II molecules. Trans. Am. Clin. Climatol. Assoc. 1990, 101:195-204. discussion 204-196.
28. Foster B., Prussin C., Liu F., Whitmire J.K., Whitton J.L. Detection of intracellular cytokines by flow cytometry. Curr. Protoc. Immunol. 2007, 24. Chapter 6, Unit 6.
29. Jain A., et al. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat. Immunol. 2001, 2:223-228.
30. Xiao L., et al. Phylogenetic analysis of Cryptosporidium parasites based on the small-subunit rRNA gene locus. Appl. Environ. Microbiol. 1999, 65:1578-1583.
31. Jain A., et al. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J. Clin. Invest. 1999, 103:1151-1158.
32. Ochs H.D., Hollenbaugh D., Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin. Immunol. 1994, 6:337-341. 1994.1042.
33. Koch F., et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 1996, 184:741-746.
34. Jain A., et al. Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Blood 2011, 118:3811-3817.
35. Vonderheide R.H., et al. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 2001, 19:3280-3287.
36. Brown M.P., et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat. Med. 1998, 4:1253-1260.
37. Sacco M.G., et al. Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome. Cancer Gene Ther. 2000, 7:1299-1306.